ARIZONA ONCOLOGY’S FLAGSTAFF OFFICE CURRENTLY ENROLLING LOCAL PATIENTS IN CANCER CLINICAL TRIALS; Trials available for breast, colon, lung and pancreatic cancers
FLAGSTAFF, Ariz. (Jan. 3, 2012)— Arizona Oncology’s Flagstaff Office, located at the Flagstaff Medical Center campus in the building of the Northern Arizona Cancer Center, is currently conducting multiple clinical trials. One of them is open to patients who require chemotherapy following breast cancer surgery. The other clinical trials are for patients with colon, lung, pancreatic, and other solid tumors. These trials are being offered locally through Arizona Oncology. Because of Arizona Oncology’s affiliation with The US Oncology Network, it has access to US Oncology Research, which gives patients access to cutting-edge nationwide research and clinical trials. US Oncology Research has played a role in the development of 43 cancer-fighting drugs approved by the Food & Drug Administration (FDA).
Current trials run by the Flagstaff office include:
- Two chemotherapy trials for breast cancer patients, who have just had their surgery. One is a national trial looking at whether adding either Adriamycin or Avastin to basic chemotherapy is of any further benefit for the patients.
- The other trial looks at a new IV drug that may be better tolerated than most chemotherapy drugs, in combination with an oral chemotherapy drug.
- Two trials, one for HER-2 positive and one for HER-2 negative breast cancer that has spread, each using a new oral agent that is not considered chemotherapy.
- One trial using a new not-yet released chemotherapeutic agent to combat early metastatic breast cancer.
- Two trials using a not-yet-released biologic drug in combination with chemotherapy—one for lung cancer that has spread and another for colon cancer that has spread.
Other trials available include one for patients with all types of cancer to study ways to prevent nausea in those undergoing chemotherapy for the first time; one to study results of oral treatments for chronic myelogenous leukemia; and yet another to study any cancers for the presence of a protein on the cells, that if positive, offers yet another new alternative biological treatment.
“Flagstaff and Northern Arizona patients who are fighting cancer don’t need to travel far to receive the most comprehensive care. It is all available right here in Flagstaff,” said Peter Mathern, MD, medical oncologist. “Thanks to our affiliation with US Oncology Research, we are able to provide these clinical trials, which offer new treatment options and renewed hope to our patients.”
Arizona Oncology’s Flagstaff office is staffed by Paul Kuefler, MD and Peter Mathern, MD, both physicians who specialize in medical oncology and hematology.
Dr. Keufler is a fellow of the American College of Physicians and has held a clinical assistant professorship at the University of Washington School of Medicine in Seattle. His articles have been published in a variety of medical journals, including Clinics in Hematology and the American Journal of Physiology. He received his medical degree from the University of Southern California and completed his internship and residency at the University of Oregon Health Sciences Center, as well as a fellowship in hematology and medical oncology at the University of Colorado Health Sciences Center.
Dr. Mathern is originally from Kosice, Czechoslovakia and is a former captain in the Czechoslovak Army. He received his medical degree from the Charles University Medical School in Prague and then completed his residency in medicine at the Vanderbilt University Medical Center. He did his research fellowship at the National Institutes of Health in Bethesda, Maryland and his clinical fellowship in oncology at the Boston University Medical Center in Massachusetts. His research has been widely published in journals including Journal of Clinical Immunology, Cytogenetics and Cell Genetics, Journal of Immunology, Pediatric Research and the Journal of Neuroimmunology.
The Arizona Oncology practice is located at 1329 N. Beaver Street in Flagstaff. For more information or to schedule an appointment, call (928) 773-2260. For more information, visit www.arizonaoncology.com.
About Arizona Oncology
Arizona Oncology is the largest group of medical professionals in Arizona devoted exclusively to cancer care. With more than 50 practicing physicians, we serve patients at more than 24 locations throughout Arizona, including Cottonwood, Deer Valley, Flagstaff, Glendale, Green Valley, Marana, Nogales, Oro Valley, Phoenix, Prescott Valley, Safford, Scottsdale, Sedona, Sierra Vista and Tucson. We are proud to provide comprehensive, compassionate, cancer care in a patient-focused, cost effective, community-based setting. Arizona Oncology provides patients with access to the latest treatments, state-of-the-art technology and access to cutting edge nationwide research and clinical trials. We believe it is beneficial when these therapies are provided in a community setting, close to patients' home and your support system. Our physicians are supported by talented clinical staff members who are sensitive to the needs of cancer patients and their caregivers. For more information, please visit www.ArizonaOncology.com.
Arizona Oncology is united in healing with The US Oncology Network, one of the nation’s largest community-based cancer treatment and research networks focused on advancing cancer care in America. As an affiliate of The US Oncology Network, Arizona Oncology is united with more than 1,000 physicians and 10,000 cancer professionals nationwide. Arizona Oncologyparticipates in clinical trials through US Oncology Research, which has helped to develop 43 FDA approved cancer therapies.For more information, visit www.usoncology.com.
About US Oncology Research
US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves more than 90 sites in more than 250 locations managing more than 200 active trials at any given time. Physicians in the research network have enrolled more than 49,600 patients in nearly 1,200 trials since inception in 1992 and have contributed to the development of 43 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.